Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study
Hongge Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxin Mu(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Liangming Zhang(Sun Yat-sen University), Yanxia Wei(Fudan University), Kewei Ma(Jilin University), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Tianjin Academy of Agricultural Sciences), Yangchun Gu(Peking University), Jian Fang(Peking University), Fang Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuhui Zhang(Xuzhou Medical College), Li Liang(Jiangsu University), Ping Sun(University of Electronic Science and Technology of China), Jinghui Wang(Jilin Academy of Agricultural Sciences), Xiaohong Wang(South China University of Technology), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Shucai Zhang(Northeastern University), Jing Zhao(University of Electronic Science and Technology of China), Qi Song(The Military General Hospital of Beijing PLA), Xia Song(Shanxi Provincial Cancer Hospital), Junjun Xu(Shanxi Provincial Cancer Hospital), Guangming Tian(Peking University), Ligong Nie(Peking University), Lei Yang(Jilin University)
Cited by 26
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Protection against persistence of hepatitis C
|The Lancet|2002|439
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311